Alterity Therapeutics Ltd has released a press release.
Phase 2 DMC Recommends Continuing Clinical Trial as Planned
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Positive Efficacy Data for ATH434 in a Primate Model of PD
- Alterity Therapeutics Raises $4.8M AUD in Placement
- ATH completes enrolment in ATH434-201 Phase 2 clinical trial
- Appendix 4E and Annual Report 2023
- Alterity Presents New Data on Multiple System Atrophy
Later from Alterity Therapeutics
- Alterity Therapeutics Raises $3.25 M AUD in Placement
- Alterity Receives a $3.9 million R&D Tax Incentive Refund
- Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
- Appendix 4E Preliminary Final Report
- Alterity Announces Completion of Phase 2 Clinical Trial
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics